Harbin Pharmaceutical Group Co

Harbin Pharmaceutical Group Co EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Harbin Pharmaceutical Group Co (600664.SS) as of Oct 16, 2026 is 31.25. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 10.09 — a change of 209.77% (higher).

EV/FCF

31.25

YoY

209.77%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Harbin Pharmaceutical Group Co is 2025 31.25 . EV/FCF (Enterprise Value to Free Cash Flow) of Harbin Pharmaceutical Group Co was 2024 10.09 . It decreases by 209.77% higher compared to the previous year.

The Harbin Pharmaceutical Group Co EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
12.44 CNY
Jan 1, 2019
-27.75 CNY
Jan 1, 2020
-11.66 CNY
Jan 1, 2021
-40.61 CNY
Jan 1, 2022
16.37 CNY
Jan 1, 2023
8.87 CNY
Jan 1, 2024
10.09 CNY
Jan 1, 2025
31.25 CNY
The Harbin Pharmaceutical Group Co EV/FCF history
YEAREV/FCFYoY
31.25+209.77%
10.09+13.79%
8.87-45.83%
16.37-140.30%
-40.61+248.34%
-11.66-57.98%
-27.75-323.07%
12.44-89.77%
121.64+7,112.76%
1.69-68.66%
5.38-39.98%
8.97—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Harbin Pharmaceutical Group Co Stock analysis

What does Harbin Pharmaceutical Group Co do? Harbin Pharmaceutical Group Co Ltd is a pharmaceutical company based in Harbin, China, operating within the Health Care sector. The company engages in the research, development, manufacture, wholesale, and retail of pharmaceutical products. It has 10,064 employees, with its headquarters located in Harbin, Heilongjiang Province. Founded through an IPO on June 29, 1993, the company is listed on the Shanghai Stock Exchange under the ticker 600664.SS. Harbin Pharmaceutical Group's primary business activities include innovative research and development in high-tech fields such as antibiotics, modern Chinese medicine, and biopharmaceuticals. The company operates across multiple sectors including antibiotics, over-the-counter drugs, health products, traditional and modern Chinese medicine, biomedicine, and pharmaceutical commerce. Its product portfolio features calcium gluconate oral solution, zinc gluconate oral solution, amoxicillin capsules, Shuanghuanglian oral solution, alprostadil injection, pediatric paracetamol Huangnamin granules, lacidipine tablets, hydrochloric acid for injection Cefotiam, ibuprofen granules, and Xingaizhonggai high calcium tablets. The company's website is https://www.hayao.com/, though the source description provided is untrusted and should not be relied upon for factual accuracy. Harbin Pharmaceutical Group Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Harbin Pharmaceutical Group Co stock

EV/FCF (Enterprise Value to Free Cash Flow) of Harbin Pharmaceutical Group Co is 31.25 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Harbin Pharmaceutical Group Co changed from 10.09 to 31.25, representing a 209.77% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Harbin Pharmaceutical Group Co since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Harbin Pharmaceutical Group Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Harbin Pharmaceutical Group Co

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Harbin Pharmaceutical Group Co